Opioid Mechanism of Action and Effects

Introduction to Opioid Receptors

Opioids primarily exert their analgesic effects through agonist activity at mu opioid receptors (MORs), with some compounds also binding to delta and kappa opioid receptors to contribute to pain relief 1
Opioids bind to four types of opioid receptors: mu (MOR), delta (DOP), kappa (KOP), and nociceptin/orphanin FQ (NOP), with MOR being the most clinically relevant for analgesia 2

MORs are highly expressed in brain regions that regulate pain perception including the periaqueductal gray, thalamus, cingulate cortex, and insula 1
MORs are also found in brain regions associated with reward (ventral tegmental area, nucleus accumbens), explaining their addictive potential 1
Opioid receptors are located throughout the central nervous system (brain and spinal cord) and in peripheral tissues 3
The brainstem respiratory center (pre-Bötzinger complex) contains MORs, which explains opioid-induced respiratory depression 1

Opioids differ from other analgesics by reducing pain perception rather than antagonizing the transmission of pain signals 4
Although sensory transmission remains intact, the subjective interpretation of pain is altered 4
Sedation and euphoria are central nervous system effects of opioid receptor activation 3

Opioids vary in binding affinity and selectivity for different opioid receptors, affecting their potency 1
Pharmacokinetics and bioavailability determine the rapidity and duration of action 1
Route of administration affects onset of action - rapid delivery to the brain (e.g., intravenous, intranasal) produces stronger reward and addiction potential 1
With repeated administration, both physical and perceptual effects diminish, leading to tolerance 1
Tolerance to analgesia develops faster than tolerance to respiratory depression, increasing overdose risk 5
Physical dependence manifests as withdrawal symptoms upon abrupt discontinuation 5
Opioid-induced hyperalgesia can develop even after a few administrations 1

Opioid receptor re-sensitization typically occurs within 3-7 days after discontinuation of opioid use, with complete resolution of tolerance, physical dependence, and hyperalgesia generally occurring within one week for most opioids 6
Tolerance to opioids develops through molecular and circuit-level adaptations in opioid receptors and their intracellular signaling cascades 6
Opioid-induced hyperalgesia can develop even after a few administrations and contributes to reduced analgesic efficacy 6, 7

Tolerance, physical dependence, and hyperalgesia generally resolve relatively rapidly after opioid discontinuation 6
For most opioids, these adaptations resolve within 3-7 days after discontinuation 6, 7
Physical dependence symptoms typically resolve within 3-7 days for most opioids 6

Methadone re-sensitization may take longer due to its long half-life, with follow-up recommended within 3 days when initiating or increasing dosage 8
Buprenorphine may have less pronounced hyperalgesia effects compared to methadone, potentially affecting re-sensitization timeframe 7, 9

Patients who have developed tolerance may require higher and more frequent doses of opioid analgesics to achieve adequate pain control due to cross-tolerance between opioids 7, 9
Risk for overdose is greatest during the first 3-7 days after opioid initiation or increase in dosage, particularly with methadone or transdermal fentanyl 8
Clinicians should evaluate benefits and harms of opioid therapy within 1-4 weeks of starting therapy or dose escalation 8, 10
Patients receiving maintenance opioid therapy demonstrate increased sensitivity to experimental pain, suggesting persistent receptor adaptations 7

The state of addiction does not resolve promptly like tolerance and physical dependence 6
Rapid re-sensitization through abrupt discontinuation can precipitate withdrawal symptoms, which can be avoided by tapering the drug slowly 6

The analgesic effects of opioids are most likely mediated through the periaqueductal gray (PAG) structure in the midbrain, which is believed to be caused by stimulation of descending inhibitory pathways in the midbrain, periaqueductal gray, and nucleus reticularis paragigantocellularis 11

Long-term opioid exposure leads to neuroplastic changes associated with excitatory amino acid (N-methyl-D-aspartate) and opioid receptors, resulting in tolerance, cross-tolerance, and opioid-induced hyperalgesia 12, 13
Tolerance to opioid analgesic effects can develop, requiring increasing doses to achieve initial effects 13
Opioid-induced hyperalgesia can occur, characterized by a paradoxical increase in pain sensitivity 12, 13

Patients receiving long-term opioid therapy may develop tolerance to the analgesic effects while still experiencing respiratory depression risks, as tolerance develops differentially to various opioid effects 13
The development of opioid-induced hyperalgesia through PAG mechanisms may contribute to diminished analgesic effectiveness over time 12